Article
Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2014
Ohue Yoshihiro, Kurose Koji, Mizote Yu, Matsumoto Hirofumi, Nishio Yumi, Isobe Midori, Fukuda Minoru, Uenaka Akiko, Oka Mikio, Nakayama Eiichi
Abstract excerpt
PURPOSE: The cancer/testis antigen XAGE1 (GAGED2a) is expressed in approximately 40% of advanced lung adenocarcinomas. We investigated the clinical relevance of the XAGE1 (GAGED2a) immune responses in patients with advanced lung adenocarcinoma. EXPERIMENTAL DESIGN: The XAGE1 (GAGED2a) antigen expression and EGFR mutation were determined with tumor tissues. The XAGE1 (GAGED2a) antibody and T-cell immune responses,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.